milnacipran has been researched along with Liver Diseases in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boinpally, R; Chen, L; Ghahramani, P; Greenberg, WM; Periclou, A; Wangsa, J | 1 |
| Dubarek, W; Kucia, K | 1 |
| Leonard, BE; Puozzo, C | 1 |
2 review(s) available for milnacipran and Liver Diseases
| Article | Year |
|---|---|
[Applications and safety of modern antidepressants in patients with liver diseases].
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cyclohexanols; Cyclopropanes; Depressive Disorder; Humans; Liver Diseases; Mianserin; Milnacipran; Mirtazapine; Monoamine Oxidase Inhibitors; Piperazines; Risk Factors; Selective Serotonin Reuptake Inhibitors; Triazoles; Venlafaxine Hydrochloride | 2007 |
Pharmacokinetics of milnacipran in comparison with other antidepressants.
Topics: Adrenergic Uptake Inhibitors; Age Factors; Antidepressive Agents; Antidepressive Agents, Tricyclic; Biological Availability; Cyclopropanes; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Half-Life; Humans; Kidney Diseases; Liver Diseases; Metabolic Clearance Rate; Milnacipran; Selective Serotonin Reuptake Inhibitors; Tissue Distribution | 1996 |
1 trial(s) available for milnacipran and Liver Diseases
| Article | Year |
|---|---|
Effect of hepatic impairment on the pharmacokinetics of levomilnacipran following a single oral dose of a levomilnacipran extended-release capsule in human participants.
Topics: Administration, Oral; Adolescent; Adult; Aged; Capsules; Case-Control Studies; Cyclopropanes; Delayed-Action Preparations; Dose-Response Relationship, Drug; Female; Humans; Liver Diseases; Male; Middle Aged; Milnacipran; Young Adult | 2014 |